kr5.11
3.95% yesterday
Stockholm, Nov 14, 05:29 pm CET
ISIN
SE0002478776
Symbol
SEZI

Senzime Stock price

kr5.11
-0.71 12.20% 1M
+0.13 2.51% 6M
-0.39 7.09% YTD
-0.99 16.23% 1Y
-6.43 55.72% 3Y
-15.80 75.56% 5Y
+0.16 3.23% 10Y
-3.38 39.81% 20Y
Stockholm, Closing price Fri, Nov 14 2025
-0.21 3.95%
ISIN
SE0002478776
Symbol
SEZI

Key metrics

Basic
Market capitalization
kr836.4m
Enterprise Value
kr744.2m
Net debt
positive
Cash
kr106.6m
Shares outstanding
157.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
9.3 | 7.7
EV/Sales
8.3 | 6.9
EV/FCF
negative
P/B
2.4
Financial Health
Equity Ratio
81.1%
Return on Equity
-34.3%
ROCE
-28.8%
ROIC
-36.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
kr89.7m | kr108.1m
EBITDA
kr-82.0m | kr-85.7m
EBIT
kr-109.6m | kr-112.2m
Net Income
kr-120.6m | kr-128.3m
Free Cash Flow
kr-124.0m
Growth (TTM | estimate)
Revenue
62.3% | 84.9%
EBITDA
28.3% | 18.4%
EBIT
19.6% | 14.5%
Net Income
8.2% | -8.1%
Free Cash Flow
3.7%
Margin (TTM | estimate)
Gross
41.9%
EBITDA
-91.4% | -79.3%
EBIT
-122.1%
Net
-134.5% | -118.7%
Free Cash Flow
-138.3%
More
EPS
kr-0.8
FCF per Share
kr-0.8
Short interest
-
Employees
54
Rev per Employee
kr1.1m
Show more

Is Senzime a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Financial data from Senzime

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
90 90
62% 62%
100%
- Direct Costs 52 52
41% 41%
58%
38 38
104% 104%
42%
- Selling and Administrative Expenses 133 133
5% 5%
148%
- Research and Development Expense 22 22
4% 4%
25%
-82 -82
28% 28%
-91%
- Depreciation and Amortization 28 28
26% 26%
31%
EBIT (Operating Income) EBIT -110 -110
20% 20%
-122%
Net Profit -121 -121
8% 8%
-134%

In millions SEK.

Don't miss a Thing! We will send you all news about Senzime directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Senzime AB engages in the development of enzyme-based biosensor technology for medical and biochemical processes and industries. It manufactures products for automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patient's neuromuscular function perioperatively and in the intensive care medicine setting. The company also distributes bioreactor systems for the pharmaceutical industry. Senzime was founded by Thomas Ambjorn Carlsson in 1999 and is headquartered in Uppsala, Sweden.

Head office Sweden
CEO Mr. Siberg
Employees 54
Founded 1999
Website senzime.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today